Department of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, India.
J Biomol Struct Dyn. 2023;41(22):13098-13112. doi: 10.1080/07391102.2023.2171138. Epub 2023 Feb 2.
is a horrifying bacteria capable of causing millions of deaths yearly across the globe. A major contribution to the success of as an ESKAPE pathogen is the abundance of virulence factors that can manipulate the innate and adaptive immune system of the individual. Currently, no vaccine is available to treat -mediated infections. In this study, we present approaches to design a stable, safe and immunogenic vaccine that could help to control the infections associated with the bacteria. Three vital pathogenic secreted toxins of , such as staphylococcal enterotoxin A (SEA), staphylococcal enterotoxin B (SEB), Toxic-shock syndrome toxin (TSST-1), were selected using the reverse vaccinology approach to design the multi-epitope vaccine (MEV). Linear B-lymphocyte, cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were predicted from these selected proteins. For designing the multi-epitope vaccine (MEV), B-cell epitopes were joined with the KK linker, CTL epitopes were joined with the AAY linker, and HTL epitopes were joined with the GPGPG linker. Finally, to increase the immune response to the vaccine, a human β-defensin-3 (hBD-3) adjuvant was added to the N-terminus of the MEV construct. The final MEV was found to be antigenic and non-allergen in nature. immune simulation and cloning analysis predicted the immune-stimulating potential of the designed MEV construct along with the cloning feasibility in the pET28a(+) vector with the expression system. This immunoinformatics study provides a platform for designing a suitable, safe and effective vaccine against .Communicated by Ramaswamy H. Sarma.
是一种可怕的细菌,每年在全球范围内导致数百万人死亡。作为 ESKAPE 病原体,能够成功的一个主要原因是其丰富的毒力因子,这些因子可以操纵个体的先天和适应性免疫系统。目前,尚无疫苗可用于治疗由引起的感染。在这项研究中,我们提出了设计稳定、安全和免疫原性疫苗的方法,以帮助控制与该细菌相关的感染。使用反向疫苗学方法选择了三种重要的致病性分泌毒素,如葡萄球菌肠毒素 A (SEA)、葡萄球菌肠毒素 B (SEB)、中毒性休克综合征毒素 (TSST-1),用于设计多表位疫苗 (MEV)。从这些选定的蛋白质中预测了线性 B 淋巴细胞、细胞毒性 T 淋巴细胞 (CTL) 和辅助 T 淋巴细胞 (HTL) 表位。为了设计多表位疫苗 (MEV),B 细胞表位与 KK 接头连接,CTL 表位与 AAY 接头连接,HTL 表位与 GPGPG 接头连接。最后,为了提高疫苗的免疫反应,在 MEV 构建体的 N 端添加了人 β-防御素-3 (hBD-3) 佐剂。最终的 MEV 被发现具有抗原性和非变应原性。免疫模拟和克隆分析预测了设计的 MEV 构建体的免疫刺激潜力,以及在 pET28a(+) 载体中与表达系统的克隆可行性。这项免疫信息学研究为设计针对的合适、安全和有效的疫苗提供了一个平台。由 Ramaswamy H. Sarma 交流。